Piper Jaffray has downgraded Allergan (NYSE:
AGN) from Overweight to Neutral and has lowered the price target from $91 to $89.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.